131I-DOTA girentuximab

N/A

Report date: 2025/11/21 17:15:30

Base Information

Drug Name131I-DOTA girentuximab

Drug Alias Name131I-DOTA-cG250131I-DOTA-girentuximab131I-girentuximab

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)Biologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibodyBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody diagnostics +[6]

Mechanisms of ActionIonising radiation emittersCarbonic anhydrase IX inhibitors

TargetsCarbonic anhydrase IX

Therapy Area/IndicationsCarcinoma, Renal Cell

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryNetherlands

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesUniversity Medical Center Nijmegen

China Registration ClassN/A

Develop Information

Active CompaniesUniversity Medical Center Nijmegen

Inactive CompaniesN/A

Active IndicationsCarcinoma, Renal Cell

Inactive IndicationsN/A

Other Information

ATC CodeN/A